Quince Therapeutics Inc (QNCX)

Currency in USD
3.420
-0.130(-3.66%)
Closed·
3.430+0.010(+0.29%)
·
QNCX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.3003.720
52 wk Range
0.7204.550
Key Statistics
Prev. Close
3.55
Open
3.5
Day's Range
3.3-3.72
52 wk Range
0.72-4.55
Volume
1.54M
Average Volume (3m)
809.59K
1-Year Change
106.0241%
Book Value / Share
0.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QNCX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.667
Upside
+124.17%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Quince Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Quince Therapeutics Inc Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Compare QNCX to Peers and Sector

Metrics to compare
QNCX
Peers
Sector
Relationship
P/E Ratio
−3.3x−3.8x−0.6x
PEG Ratio
−1.050.100.00
Price/Book
179.8x4.0x2.6x
Price / LTM Sales
-15.9x3.4x
Upside (Analyst Target)
125.4%24.1%41.5%
Fair Value Upside
Unlock−12.0%5.5%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.667
(+124.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy8.00+133.92%-MaintainJan 09, 2026
Citizens
Buy8.00+133.92%-MaintainJan 06, 2026
Citizens
Buy8.00+133.92%-MaintainDec 11, 2025
Citizens
Buy8.00+133.92%-MaintainOct 03, 2025
Citizens JMP
Buy8.00+133.92%-MaintainSep 26, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.25 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

QNCX Income Statement

People Also Watch

1.990
GANX
+9.94%
2.890
ESPR
-4.93%
74.17
ATRO
-0.72%
5.9800
SVRA
+2.75%
7.71
VNDA
+3.21%

FAQ

What Is the Quince Therapeutics (QNCX) Stock Price Today?

The Quince Therapeutics stock price today is 3.420

What Stock Exchange Does Quince Therapeutics Trade On?

Quince Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Quince Therapeutics?

The stock symbol for Quince Therapeutics is "QNCX."

What Is the Quince Therapeutics Market Cap?

As of today, Quince Therapeutics market cap is 187.37M.

What Is Quince Therapeutics's Earnings Per Share (TTM)?

The Quince Therapeutics EPS (TTM) is -1.21.

When Is the Next Quince Therapeutics Earnings Date?

Quince Therapeutics will release its next earnings report on Mar 03, 2026.

From a Technical Analysis Perspective, Is QNCX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Quince Therapeutics Stock Split?

Quince Therapeutics has split 0 times.

How Many Employees Does Quince Therapeutics Have?

Quince Therapeutics has 36 employees.

What is the current trading status of Quince Therapeutics (QNCX)?

As of Jan 21, 2026, Quince Therapeutics (QNCX) is trading at a price of 3.420, with a previous close of 3.550. The stock has fluctuated within a day range of 3.300 to 3.720, while its 52-week range spans from 0.720 to 4.550.

What Is Quince Therapeutics (QNCX) Price Target According to Analysts?

The average 12-month price target for Quince Therapeutics is USD7.667, with a high estimate of USD10 and a low estimate of USD5. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +124.17% Upside potential.

What Is the QNCX Premarket Price?

QNCX's last pre-market stock price is 3.450. The pre-market share volume is 29,680.000, and the stock has decreased by -0.100, or -2.820%.

What Is the QNCX After Hours Price?

QNCX's last after hours stock price is 3.430, the stock has decreased by 0.010, or 0.290%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.